Endologix, Inc. (NASDAQ:ELGX) Short Interest Update
Endologix, Inc. (NASDAQ:ELGX) saw a significant increase in short interest in June. As of June 30th, there was short interest totalling 1,864,300 shares, an increase of 62.9% from the May 30th total of 1,144,500 shares. Currently, 18.9% of the shares of the company are sold short. Based on an average trading volume of 316,400 shares, the short-interest ratio is currently 5.9 days.
A number of hedge funds and other institutional investors have recently made changes to their positions in ELGX. Deutsche Bank AG lifted its stake in Endologix by 121.3% in the 4th quarter. Deutsche Bank AG now owns 433,335 shares of the medical instruments supplier’s stock worth $309,000 after purchasing an additional 237,555 shares in the last quarter. Norges Bank purchased a new stake in Endologix in the 4th quarter worth $545,000. Macquarie Group Ltd. purchased a new stake in Endologix in the 4th quarter worth $46,000. Jane Street Group LLC lifted its stake in Endologix by 54.6% in the 4th quarter. Jane Street Group LLC now owns 93,572 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 33,044 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its stake in Endologix by 17.3% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,941,830 shares of the medical instruments supplier’s stock worth $1,390,000 after purchasing an additional 286,366 shares in the last quarter. 48.67% of the stock is owned by institutional investors and hedge funds.
Several equities analysts have recently issued reports on ELGX shares. Zacks Investment Research lowered EXACT Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Finally, Stifel Nicolaus set a $7.00 price objective on Endologix and gave the company a “hold” rating in a report on Monday, April 1st. Two analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $25.63.
Endologix (NASDAQ:ELGX) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported ($1.12) earnings per share for the quarter, beating the consensus estimate of ($1.56) by $0.44. Endologix had a negative return on equity of 173.52% and a negative net margin of 54.72%. The business had revenue of $35.61 million during the quarter, compared to analyst estimates of $34.18 million. On average, analysts forecast that Endologix will post -3.65 earnings per share for the current fiscal year.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.
See Also: What is the Current Ratio?
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.